UK & Europe Next-Day Delivery — Order before 1pm.Worldwide Delivery — Estimated delivery within 5–10 days.
Retatrutide GLP-1 GIP & Glucagon, 40mg
** See Body Composition Chart Before Purchase **
Disclaimer: The following product is intended solely for research purposes.
Retatrutide better than Wegovy and Mounjaro?
Whilst Wegovy targets GLP-1 and Mounjaro targets GLP-1 and GIP, neither target glucagon receptors. This means that Retatrutide, with three targets, is more effective.
Retatrutide helps lose more weight in a shorter amount of time. Studies show that Retatrutide has achieved 30% weight loss in just over 3 months. This is the highest percentage weight loss ever recorded for an obesity drug.
One of the most advanced multi-receptor weight-loss pens
Outperforming many current weight-loss medications
Reduces appetite
Fat loss
Increases energy expenditure (fat burn)
An innovative pen that is increasingly gaining popularity across the UK and worldwide. Activates GLP-1, GIP & Glucagon receptors simultaneously, delivering extreme appetite control, accelerated fat loss and metabolic enhancement.
Retatrutide is a peptide that simultaneously targets three critical metabolic receptors — GLP-1, GIP & Glucagon — a significant advancement at the forefront of science.
The pen is supplied as a complete kit, with everything required included.
Designed to support extensive scientific exploration of:
Weight reduction
Improved glucose management
Enhanced metabolic function
Pen fill
40 mg
Purity
98.6%
Pen price
£155.00
Certificate of analysis
Issued against pen reference PEN-RET40.
The pen must be stored in a refrigerator at 2°C–8°C (36°F–46°F), do not freeze.
Age disclaimer: Researchers must be aged 18 or above to purchase this product.
As a direct laboratory we issue Certificates of Analysis (COA).